title: Lipoxin receptor agonist, may be a potential treatment for hemorrhagic shock-induced acute lung injury.
abstract: The main pathogenesis of acute lung injury induced by hemorrhagic shock is increasingly recognized as an inflammatory process. BML-111, a lipoxin receptor agonist, has been demonstrated to promote acute inflammatory resolution by reduction of pro-inflammatory cytokines, attenuation of neutrophilic infiltration, and increasing macrophage phagocytosis of apoptotic neutrophils. Meanwhile, lipoxins and lipoxin analogues have been reported to play pro-resolving and anti-inflammatory effects in many disease models including cerebral ischemia, dorsal air pouch, peritonitis, and so on. Therefore, we hypothesize that BML-111 may be implicated in pathogenesis of hemorrhagic shock-induced acute lung injury.
authors.affiliation: Department of Anaesthesiology and Critical Care, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Gong
authors.forename: Hong-Bin
authors.initials: HB
authors.lastname: Li
authors.forename: Si
authors.initials: S
authors.lastname: Guo
authors.forename: You
authors.initials: Y
authors.lastname: Shang
authors.forename: Shang-Long
authors.initials: SL
authors.lastname: Yao
mesh_terms: D055371:Acute Lung Injury / Q000188:drug therapy* / Q000209:etiology; D000818:Animals; D051381:Rats; D044067:Receptors, Lipoxin / Q000819:agonists*; D012771:Shock, Hemorrhagic / Q000150:complications / Q000188:drug therapy*
chemical_list: D044067:Receptors, Lipoxin